PeriRx will launch its molecular saliva test that analyzes biomarkers to detect oral cancer and diabetes in late spring, the company announced.
The noninvasive test is designed for front-line healthcare practitioners and enables them to detect disease earlier, according to PeriRx.
The test is based on research funded by the National Institutes of Health (NIH) with initial discovery and prevalidation work by David Wong, DMD, DMSc, an associate dean of research and a professor of oral biology at the University of California, Los Angeles School of Dentistry, who has worked on salivary diagnostics.
The discriminatory salivary biomarkers have been clinically validated in multiple large trials, including studies in collaboration with the National Cancer Institute, the University of Michigan, Michigan State University, and the Providence Health System in Detroit, according to the company.
